このエントリーをはてなブックマークに追加
ID 13715
Eprint ID
13715
フルテキストURL
Thumnail 110_31.pdf 2.27 MB
タイトル(別表記)
2β-(3-Hydroxypropoxy)1α,25-Dihydroxyvitamin D(3)(ED-71), increases bone mass by stimulating bone formation in hypophosphatemic mice
著者
越智 英明 岡山大学医学部小児科学講座
抄録
To determine the effects of ED-71, a new active vitamin D3 analogue, on bone, we examined the action of ED-71 and 1α,25(OH)(2)D(3), using hypophosphatemic (Hyp) mice, a model for X-linked hypophosphatemic rickets in humans. ED-71 has the unique characteristics of a longer half-life in serum, a higher binding affinity to serum vitamin D binding protein and lower affinity to the vitamin D receptor than 1α,25(OH)(2)D(3). Hyp mice were treated with 10-1200 pmol/kg/day of ED-71, 40-400 pmol/kg/day of 1α,25(OH)(2)D(3), or the vehicle alone, administered daily for 21 days by subcutaneous injection. ED-71 at doses of 100-400 pmol/kg/day, dose-dependently effects in increased bone size and bone mineral density (BMD) without causing hypercalcemia. However 1α,25(OH)(2)D(3) at a dose of 400 pmol/kg/day, demonstrated only slight increases in bone size and BMD with hypercalcemia. These findings suggest that ED-71 may be more beneficial in the treatment of X-linked hypophosphatemic rickets than 1α,25(OH)(2)D(3).
キーワード
ED-71
Hyp mouse
BMD
Ca
備考
原著
発行日
1998-06-25
出版物タイトル
岡山医学会雑誌
出版物タイトル(別表記)
Journal of Okayama Medical Association
110巻
1-6号
出版者
岡山医学会
出版者(別表記)
Okayama Medical Association
開始ページ
31
終了ページ
37
ISSN
0030-1558
NCID
AN00032489
資料タイプ
学術雑誌論文
オフィシャル URL
https://www.jstage.jst.go.jp/article/joma1947/110/1-6/110_1-6_31/_article/-char/ja/
関連URL
http://www.okayama-u.ac.jp/user/oma/index.html
参考文献
1) Rasmussen H and Tenenhouse HS : Hypophosphatemias; In the metabolic basis of inherited disease, Scriver CR, Beaudet AL, Sly WS, Valle D eds, T, 6th edn. McGraw Hill, New York (1989) pp 2581-2601.
2) Goodyear PR, Kronik JB, Jequir S, Reade TM and Scriver CR : Nephrocalcinosis and its relationship to treatment of hereditary rickets. J Pediatr (1987) 111, 700-704.
3) Weber G, Gazzuffi MA, Frisone F, de Angelis M, Pasolini D, Tomaselli V and Chiumello G : Nephrocalcinosis in children and adolescents: sonographic evaluation during longterm treatment with 1,25-dihydroxycholecalciferol. Child Nephrol Urol (1988-89) 9, 273-276.
4) Reusz GS, Hoyer PF, Lucas M, Krohn HP, Ehrich JHH and Brodehl J : X linked hypophosphatemia: treatmest, hight gain and nephrocalcinosis. Arch Dis Child (1990) 65, 1125-1128.
5) Seino Y, Yamaoka K, Ishida M, Tanaka Y, Yabuuchi H, Tohira Y, Fukushima M and Nishii Y : Plasma clearance for high doses of exogenous 1,25-dihydroxy [23,24(n)-3H] cholecalciferol in X-linked hypophosphatemic mice. Biomed Res (1982) 3, 683-687.
6) Yamaoka K, Seino Y, Satomura K, Tanaka Y, Yabuuchi H and Haussler MR : Abnormal relationship between serum phosphate concentration and renal 25 hydroxycholecalciferol-1-alpha-hydroxylase activity in X-linked hypophosphatemic mice. Miner Electrolyte Metab (1986) 12, 576-580.
7) Yamate T, Tanaka H, Nagai Y, Yamato H, Taniguchi N, Nakamura T and Seino Y : Bone-forming ability of 24R,25-dihydrovitamin D3 in the hypophosphatemic mouse. J Bone Miner Res (1994) 9, 1967-1974.
8) Okano T, Tsugawa N, Masuda S, Takeuchi A, Kobayashi T, Takita Y and Nishii Y : Regulatory activities of 2β-(3-hydroxypropoxy)1α,25-dihydroxycholecalciferol D3, a novel sythetic vitamin D3 derivative on calcium metabolism. Biochem Biophys Res Commum (1989) 163, 1444-1449.
9) Okano T, Tsugawa N, Masuda S, Takeuchi A, Kobayashi T and Nishii Y : A Novel Synthetic Vitamin D3 Analogue, 2-Beta-(3-Hydroxypropoxy)-Calcitriol (ED-71): Its biological activities and pharmacological effects on calcium metabolism. Contrib Nephrol (1991) 91,116-122.
10) Sato K, Nishii Y, Woodiel FN and Raisz LG : Effects of two new vitamin D3 derivatives, 22-oxa-1α,25-dihydroxyvitamin D3 (OCT) and 2β-(3-Hydroxypropoxy) 1α,25-dihydroxyvitamin D3 (OCT) and 2β-(3-Hydroxypropoxy) 1α,25-dihydroxyvitamin D3 (ED-71), on bone metabolism in organ culture. Bone (1993) 14, 47-51.
11) Tsurukami H, Nakamura T, Suzuki K, Sato K, Higuchi Y and Nishii Y : A Novel Synthetic Vitamin D Analogue, 2β-(3-Hydroxypropoxy) 1α,25-Dihydroxyvitamin D3 (ED-71), Increases Bone Mass by Stimulating the Bone Formation in Normal and Ovariectomized Rats. Calcif Tissue Int (1994) 54, 142-149.
12) Schmidt IU, Dobnig H and Turner RT : Intermittent parathyroid hormone treatment inecreases osteoblast number, steady state messanger ribonucleic acid levels for osteocalcin, and bone formation in tibial metaphysis of hypophysectomzed female rats. Endocrinology (1995) 136, 5127-5134.
13) 成田裕一郎:実験的骨減少ラットに対するh-PTH 間欠投与の影響―椎体の海綿骨と皮質骨の骨形体計測による検討―.日本整形外科学会雑誌(1995)69,1027-1036.
言語
Japanese
著作権者
岡山医学会
論文のバージョン
publisher
査読
有り
Eprints Journal Name
joma